Market research
CLLS Cellectis SA
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 343M
- P/E ratio
- Not available
- Analyst target
- 7.6
- Dividend yield
- Not available
- Beta
- 2.75
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US15117K1034
- Market cap
- 343M
- P/E ratio
- Not available
- Analyst target
- 7.6
- Dividend yield
- Not available
- Beta
- 2.75
About
About Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CLLS discussion.
5 years, 4 months ago
Cellectis S.A is currently in a long term downtrend where the price is trading 32.0% below its 200 day moving average.
From a valuation standpoint, the stock is 99.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 11.3.
Cellectis S.A's total revenue rose by 213.8% to $14M since the same quarter in the previous year.
Its net income has dropped by 5.6% to $-39M since the same quarter in the previous year.
Finally, its free cash flow fell by 838.0% to $-52M since the same quarter in the previous year.
Based on the above factors, Cellectis S.A gets an overall score of 2/5.